COVID-19 infection is not associated with immediate changes in multiple sclerosis symptom severity or disability.

The FDA has granted Fast Track designation to LPCN 1148 for the treatment of sarcopenia in patients with decompensated cirrhosis.

A recent study finds health care spending in the United States reached $4.9 trillion and increased 7.5 percent in 2023.

Upadacitinib demonstrated long-term efficacy for the treatment of ankylosing spondylitis among patients who failed to respond to prior biologic therapy.

A recent study finds that the prevalence of post-COVID-19 condition was 8.4 percent among U.S. adults in 2023.

Higher FT4 levels were associated with increased risks for knee OA prevalence, severity, and progression, especially among patients with greater joint loading.

Black children are suspected to have experienced child abuse at higher rates than children of other racial and ethnic backgrounds.

Despite advances, there remain gaps in the understanding of and personalized treatment for chronic pain in rheumatology, especially among women.

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

Patients with SLE have a higher prevalence of primary headaches vs those with RA or pSS, but similar percentages were found when comparing healthy controls.